{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T19:25:38Z","timestamp":1790623538095,"version":"4.1.0"},"reference-count":191,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1016\/j.bcp.2019.04.009","type":"journal-article","created":{"date-parts":[[2019,4,9]],"date-time":"2019-04-09T21:04:46Z","timestamp":1554843886000},"page":"112-125","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":47,"special_numbering":"C","title":["Risks and benefits of corticosteroids in arthritic diseases in the clinic"],"prefix":"10.1016","volume":"165","author":[{"given":"Ioanna","family":"Petta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Peene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Elewaut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Vereecke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karolien","family":"De Bosscher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.bcp.2019.04.009_b0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1677\/JOE-07-0309","article-title":"Diamonds are forever: the cortisone legacy","volume":"195","author":"Hillier","year":"2007","journal-title":"J. Endocrinol."},{"key":"10.1016\/j.bcp.2019.04.009_b0010","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/B978-0-12-802175-0.00039-5","article-title":"Chapter 39 \u2013 nongenomic effects of glucocorticoids: translation from physiology to clinic","volume":"2","author":"Gong","year":"2017","journal-title":"Stress Neuroendocrinol. Neurobiol."},{"issue":"Suppl. 2","key":"10.1016\/j.bcp.2019.04.009_b0015","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1186\/ar4686","article-title":"The value of glucocorticoid co-therapy in different rheumatic diseases\u2013positive and adverse effects","volume":"16","author":"van der Goes","year":"2014","journal-title":"Arthritis Res. Ther."},{"issue":"1","key":"10.1016\/j.bcp.2019.04.009_b0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.rdc.2015.08.009","article-title":"Glucocorticoids for management of polymyalgia rheumatica and giant cell arteritis","volume":"42","author":"Matteson","year":"2016","journal-title":"Rheum. Dis. Clin. North Am."},{"issue":"5 Suppl. 68","key":"10.1016\/j.bcp.2019.04.009_b0025","first-page":"S126","article-title":"Glucocorticoids in systemic lupus erythematosus","volume":"29","author":"Mosca","year":"2011","journal-title":"Clin. Exp. Rheumatol."},{"issue":"5","key":"10.1016\/j.bcp.2019.04.009_b0030","first-page":"556","article-title":"Systemic vasculitis","volume":"83","author":"Sharma","year":"2011","journal-title":"Am. Fam. Phys."},{"issue":"16","key":"10.1016\/j.bcp.2019.04.009_b0035","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1056\/NEJMra050541","article-title":"Antiinflammatory action of glucocorticoids\u2013new mechanisms for old drugs","volume":"353","author":"Rhen","year":"2005","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.bcp.2019.04.009_b0040","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1128\/MMBR.00064-15","article-title":"The interactome of the glucocorticoid receptor and its influence on the actions of glucocorticoids in combatting inflammatory and infectious diseases","volume":"80","author":"Petta","year":"2016","journal-title":"Microbiol. Mol. Biol. Rev."},{"issue":"1","key":"10.1016\/j.bcp.2019.04.009_b0045","doi-asserted-by":"crossref","first-page":"8941","DOI":"10.1038\/s41598-017-09246-6","article-title":"Glucocorticoid Receptor-mediated transactivation is hampered by Striatin-3, a novel interaction partner of the receptor","volume":"7","author":"Petta","year":"2017","journal-title":"Sci. Rep."},{"issue":"6","key":"10.1016\/j.bcp.2019.04.009_b0050","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1042\/cs0940557","article-title":"Anti-inflammatory actions of glucocorticoids: molecular mechanisms","volume":"94","author":"Barnes","year":"1998","journal-title":"Clin. Sci. (Lond)."},{"issue":"3","key":"10.1016\/j.bcp.2019.04.009_b0055","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.iac.2005.05.003","article-title":"Molecular mechanisms and cellular effects of glucocorticosteroids","volume":"25","author":"Barnes","year":"2005","journal-title":"Immunol. Aller. Clin. North Am."},{"issue":"4","key":"10.1016\/j.bcp.2019.04.009_b0060","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.jhep.2011.08.025","article-title":"The interaction of hepatic lipid and glucose metabolism in liver diseases","volume":"56","author":"Bechmann","year":"2012","journal-title":"J. Hepatol."},{"issue":"2","key":"10.1016\/j.bcp.2019.04.009_b0065","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1111\/brv.12178","article-title":"De novo lipogenesis in the liver in health and disease: more than just a shunting yard for glucose","volume":"91","author":"Sanders","year":"2016","journal-title":"Biol. Rev. Camb. Philos Soc."},{"issue":"11","key":"10.1016\/j.bcp.2019.04.009_b0070","doi-asserted-by":"crossref","first-page":"9453","DOI":"10.3390\/nu7115475","article-title":"The subtle balance between lipolysis and lipogenesis: a critical point in metabolic homeostasis","volume":"7","author":"Saponaro","year":"2015","journal-title":"Nutrients"},{"issue":"25","key":"10.1016\/j.bcp.2019.04.009_b0075","doi-asserted-by":"crossref","first-page":"13504","DOI":"10.1073\/pnas.94.25.13504","article-title":"Glucocorticoid-mediated repression of nuclear factor-kappaB-dependent transcription involves direct interference with transactivation","volume":"94","author":"De Bosscher","year":"1997","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"8","key":"10.1016\/j.bcp.2019.04.009_b0080","doi-asserted-by":"crossref","first-page":"3919","DOI":"10.1073\/pnas.97.8.3919","article-title":"Glucocorticoids repress NF-kappaB-driven genes by disturbing the interaction of p65 with the basal transcription machinery, irrespective of coactivator levels in the cell","volume":"97","author":"De Bosscher","year":"2000","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"6","key":"10.1016\/j.bcp.2019.04.009_b0085","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1172\/JCI60006","article-title":"Glucocorticoid receptor dimerization induces MKP1 to protect against TNF-induced inflammation","volume":"122","author":"Vandevyver","year":"2012","journal-title":"J. Clin. Invest."},{"issue":"1 Suppl 1","key":"10.1016\/j.bcp.2019.04.009_b0090","first-page":"53","article-title":"GILZ (glucocorticoid-induced leucine zipper), a mediator of the anti-inflammatory and immunosuppressive activity of glucocorticoids","volume":"22","author":"Riccardi","year":"2010","journal-title":"Ann Ig."},{"issue":"6","key":"10.1016\/j.bcp.2019.04.009_b0095","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1101\/gr.188581.114","article-title":"Genomic redistribution of GR monomers and dimers mediates transcriptional response to exogenous glucocorticoid in vivo","volume":"25","author":"Lim","year":"2015","journal-title":"Genome Res."},{"issue":"1","key":"10.1016\/j.bcp.2019.04.009_b0100","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1038\/s41467-018-03780-1","article-title":"Cryptic glucocorticoid receptor-binding sites pervade genomic NF-kappaB response elements","volume":"9","author":"Hudson","year":"2018","journal-title":"Nat. Commun."},{"issue":"11","key":"10.1016\/j.bcp.2019.04.009_b0105","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1136\/annrheumdis-2017-212762","article-title":"Glucocorticoid receptor in stromal cells is essential for glucocorticoid-mediated suppression of inflammation in arthritis","volume":"77","author":"Koenen","year":"2018","journal-title":"Ann. Rheum Dis."},{"issue":"10","key":"10.1016\/j.bcp.2019.04.009_b0110","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/ncprheum0898","article-title":"Genomic and nongenomic effects of glucocorticoids","volume":"4","author":"Stahn","year":"2008","journal-title":"Nat. Clin. Pract. Rheumatol."},{"issue":"8","key":"10.1016\/j.bcp.2019.04.009_b0115","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1136\/ard.61.8.718","article-title":"Standardised nomenclature for glucocorticoid dosages and glucocorticoid treatment regimens: current questions and tentative answers in rheumatology","volume":"61","author":"Buttgereit","year":"2002","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.bcp.2019.04.009_b0120","doi-asserted-by":"crossref","first-page":"12621","DOI":"10.1038\/ncomms12621","article-title":"Sequences flanking the core-binding site modulate glucocorticoid receptor structure and activity","volume":"7","author":"Schone","year":"2016","journal-title":"Nat. Commun."},{"issue":"4","key":"10.1016\/j.bcp.2019.04.009_b0125","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1023\/A:1026445108136","article-title":"Bioenergetics of human peripheral blood mononuclear cell metabolism in quiescent, activated, and glucocorticoid-treated states","volume":"20","author":"Schmid","year":"2000","journal-title":"Biosci. Rep."},{"issue":"10","key":"10.1016\/j.bcp.2019.04.009_b0130","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1007\/s12098-008-0210-7","article-title":"Pulse steroid therapy","volume":"75","author":"Sinha","year":"2008","journal-title":"Indian J. Pediatr."},{"issue":"6","key":"10.1016\/j.bcp.2019.04.009_b0135","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1136\/annrheumdis-2016-210715","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update","volume":"76","author":"Smolen","year":"2017","journal-title":"Ann. Rheum. Dis."},{"issue":"5","key":"10.1016\/j.bcp.2019.04.009_b0140","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s11940-000-0045-7","article-title":"Neuropsychiatric Systemic Lupus Erythematosus","volume":"2","author":"Navarrete","year":"2000","journal-title":"Curr. Treat Opt. Neurol."},{"issue":"1","key":"10.1016\/j.bcp.2019.04.009_b0145","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1136\/ard.60.1.61","article-title":"Short term effects of corticosteroid pulse treatment on disease activity and the wellbeing of patients with active rheumatoid arthritis","volume":"60","author":"Jacobs","year":"2001","journal-title":"Ann. Rheum. Dis."},{"issue":"1","key":"10.1016\/j.bcp.2019.04.009_b0150","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1111\/bcp.12295","article-title":"Pharmacokinetics of oral vs. intravenous dexamethasone in patients hospitalized with community-acquired pneumonia","volume":"78","author":"Spoorenberg","year":"2014","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.bcp.2019.04.009_b0155","first-page":"CD012629","article-title":"Villa-Roel C, Rowe BH. Intramuscular versus oral corticosteroids to reduce relapses following discharge from the emergency department for acute asthma","volume":"6","author":"Kirkland","year":"2018","journal-title":"Cochrane Database Syst. Rev."},{"issue":"8","key":"10.1016\/j.bcp.2019.04.009_b0160","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1093\/rheumatology\/32.8.734","article-title":"Intramuscular methylprednisolone is superior to pulse oral methylprednisolone during the induction phase of chrysotherapy","volume":"32","author":"Choy","year":"1993","journal-title":"Br. J. Rheumatol."},{"issue":"1","key":"10.1016\/j.bcp.2019.04.009_b0165","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1136\/ard.2007.086561","article-title":"Overnight variations in cortisol, interleukin 6, tumour necrosis factor alpha and other cytokines in people with rheumatoid arthritis","volume":"68","author":"Perry","year":"2009","journal-title":"Ann. Rheum. Dis."},{"issue":"2","key":"10.1016\/j.bcp.2019.04.009_b0170","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1208\/s12248-008-9038-3","article-title":"Assessment of the impact of dosing time on the pharmacokinetics\/pharmacodynamics of prednisolone","volume":"10","author":"Xu","year":"2008","journal-title":"AAPS J."},{"issue":"9608","key":"10.1016\/j.bcp.2019.04.009_b0175","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S0140-6736(08)60132-4","article-title":"Efficacy of modified-release versus standard prednisone to reduce duration of morning stiffness of the joints in rheumatoid arthritis (CAPRA-1): a double-blind, randomised controlled trial","volume":"371","author":"Buttgereit","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.bcp.2019.04.009_b0180","first-page":"555","article-title":"Cost-effectiveness of modified-release prednisone in the treatment of moderate to severe rheumatoid arthritis with morning stiffness based on directly elicited public preference values","volume":"5","author":"Dunlop","year":"2013","journal-title":"Clinicoecon. Outcomes Res."},{"issue":"8","key":"10.1016\/j.bcp.2019.04.009_b0185","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1093\/rheumatology\/ket145","article-title":"A simple model that suggests possible cost savings when modified-release prednisone 5 mg\/day is added to current treatment in patients with active rheumatoid arthritis","volume":"52","author":"Boers","year":"2013","journal-title":"Rheumatology (Oxford)."},{"issue":"10055","key":"10.1016\/j.bcp.2019.04.009_b0190","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1016\/S0140-6736(16)30173-8","article-title":"Rheumatoid arthritis","volume":"388","author":"Smolen","year":"2016","journal-title":"Lancet"},{"issue":"9746","key":"10.1016\/j.bcp.2019.04.009_b0195","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/S0140-6736(10)60826-4","article-title":"Rheumatoid arthritis","volume":"376","author":"Scott","year":"2010","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.bcp.2019.04.009_b0200","first-page":"175","article-title":"One year in review 2018: pathogenesis of rheumatoid arthritis","volume":"36","author":"Calabresi","year":"2018","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.bcp.2019.04.009_b0205","article-title":"Disease modifying anti-rheumatic drugs (DMARD). StatPearls","author":"Benjamin","year":"2019","journal-title":"Treasure Island"},{"issue":"2","key":"10.1016\/j.bcp.2019.04.009_b0210","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s40744-017-0073-3","article-title":"Treatment with biologicals in rheumatoid arthritis: an overview","volume":"4","author":"Rein","year":"2017","journal-title":"Rheumatol. Ther."},{"key":"10.1016\/j.bcp.2019.04.009_b0215","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1196\/annals.1351.025","article-title":"Are glucocorticoids DMARDs?","volume":"1069","author":"Bijlsma","year":"2006","journal-title":"Ann. NY. Acad. Sci."},{"issue":"3","key":"10.1016\/j.bcp.2019.04.009_b0220","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1136\/annrheumdis-2015-208337","article-title":"European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update","volume":"75","author":"Gossec","year":"2016","journal-title":"Ann. Rheum. Dis."},{"issue":"12","key":"10.1016\/j.bcp.2019.04.009_b0225","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1136\/annrheumdis-2013-203249","article-title":"EULAR evidence-based and consensus-based recommendations on the management of medium to high-dose glucocorticoid therapy in rheumatic diseases","volume":"72","author":"Duru","year":"2013","journal-title":"Ann. Rheum. Dis."},{"issue":"1","key":"10.1016\/j.bcp.2019.04.009_b0230","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1136\/annrheumdis-2014-205489","article-title":"Methotrexate in combination with other DMARDs is not superior to methotrexate alone for remission induction with moderate-to-high-dose glucocorticoid bridging in early rheumatoid arthritis after 16 weeks of treatment: the CareRA trial","volume":"74","author":"Verschueren","year":"2015","journal-title":"Ann. Rheum. Dis."},{"issue":"7","key":"10.1016\/j.bcp.2019.04.009_b0235","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1136\/annrheumdis-2013-204788","article-title":"Randomised comparison of initial triple DMARD therapy with methotrexate monotherapy in combination with low-dose glucocorticoid bridging therapy; 1-year data of the tREACH trial","volume":"73","author":"de Jong","year":"2014","journal-title":"Ann. Rheum. Dis."},{"issue":"1","key":"10.1016\/j.bcp.2019.04.009_b0240","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1136\/annrheumdis-2013-203440","article-title":"Remission induction comparing infliximab and high-dose intravenous steroid, followed by treat-to-target: a double-blind, randomised, controlled trial in new-onset, treatment-naive, rheumatoid arthritis (the IDEA study)","volume":"73","author":"Nam","year":"2014","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.bcp.2019.04.009_b0245","first-page":"CD006356","article-title":"Effects of glucocorticoids on radiological progression in rheumatoid arthritis","volume":"1","author":"Kirwan","year":"2007","journal-title":"Cochrane Database Syst. Rev."},{"issue":"2","key":"10.1016\/j.bcp.2019.04.009_b0250","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1002\/art.10083","article-title":"COBRA combination therapy in patients with early rheumatoid arthritis: long-term structural benefits of a brief intervention","volume":"46","author":"Landewe","year":"2002","journal-title":"Arthrit. Rheum."},{"issue":"5","key":"10.1016\/j.bcp.2019.04.009_b0255","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1002\/art.21809","article-title":"Followup radiographic data on patients with rheumatoid arthritis who participated in a two-year trial of prednisone therapy or placebo","volume":"54","author":"Jacobs","year":"2006","journal-title":"Arthrit. Rheum."},{"issue":"4","key":"10.1016\/j.bcp.2019.04.009_b0260","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.jbspin.2017.12.002","article-title":"Controversies in rheumatoid arthritis glucocorticoid therapy","volume":"85","author":"Ruyssen-Witrand","year":"2018","journal-title":"Joint Bone Spine"},{"issue":"9430","key":"10.1016\/j.bcp.2019.04.009_b0265","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0140-6736(04)16676-2","article-title":"Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial","volume":"364","author":"Grigor","year":"2004","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.bcp.2019.04.009_b0270","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1136\/annrheumdis-2011-200632","article-title":"Short- and long-term efficacy of intra-articular injections with betamethasone as part of a treat-to-target strategy in early rheumatoid arthritis: impact of joint area, repeated injections, MRI findings, anti-CCP, IgM-RF and CRP","volume":"71","author":"Hetland","year":"2012","journal-title":"Ann. Rheum. Dis."},{"issue":"4","key":"10.1016\/j.bcp.2019.04.009_b0275","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1136\/annrheumdis-2012-202735","volume":"73","author":"Horslev-Petersen","year":"2014","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.bcp.2019.04.009_b0280","doi-asserted-by":"crossref","DOI":"10.1093\/rheumatology\/key122","article-title":"Effect of cumulative exposure to corticosteroid and DMARD on radiographic progression in rheumatoid arthritis: results from the ESPOIR cohort","author":"Louveau","year":"2018","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"10.1016\/j.bcp.2019.04.009_b0285","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1136\/annrheumdis-2011-201162","article-title":"Induction therapy with a combination of DMARDs is better than methotrexate monotherapy: first results of the tREACH trial","volume":"72","author":"de Jong","year":"2013","journal-title":"Ann. Rheum. Dis."},{"issue":"9860","key":"10.1016\/j.bcp.2019.04.009_b0290","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0140-6736(12)60680-1","article-title":"Polymyalgia rheumatica","volume":"381","author":"Kermani","year":"2013","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.bcp.2019.04.009_b0295","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1056\/NEJMra022694","article-title":"Medium- and large-vessel vasculitis","volume":"349","author":"Weyand","year":"2003","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.bcp.2019.04.009_b0300","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/nrrheum.2012.97","article-title":"Clinical features of polymyalgia rheumatica and giant cell arteritis","volume":"8","author":"Salvarani","year":"2012","journal-title":"Nat. Rev. Rheumatol."},{"issue":"9","key":"10.1016\/j.bcp.2019.04.009_b0305","doi-asserted-by":"crossref","first-page":"ITC65","DOI":"10.7326\/AITC201705020","article-title":"Polymyalgia Rheumatica","volume":"166","author":"Matteson","year":"2017","journal-title":"Ann. Int. Med."},{"issue":"1","key":"10.1016\/j.bcp.2019.04.009_b0310","doi-asserted-by":"crossref","first-page":"e2","DOI":"10.1097\/WNO.0000000000000343","article-title":"Giant cell arteritis","volume":"36","author":"Francis","year":"2016","journal-title":"J. Neuroophthalmol."},{"issue":"10","key":"10.1016\/j.bcp.2019.04.009_b0315","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1136\/annrheumdis-2015-207578","volume":"74","author":"Dejaco","year":"2015","journal-title":"Ann. Rheum. Dis."},{"issue":"1","key":"10.1016\/j.bcp.2019.04.009_b0320","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1093\/rheumatology\/kep303a","article-title":"BSR and BHPR guidelines for the management of polymyalgia rheumatica","volume":"49","author":"Dasgupta","year":"2010","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"10.1016\/j.bcp.2019.04.009_b0325","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1136\/ard.2009.114579","article-title":"Patient and rheumatologist perspectives on glucocorticoids: an exercise to improve the implementation of the European League Against Rheumatism (EULAR) recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases","volume":"69","author":"van der Goes","year":"2010","journal-title":"Ann. Rheum. Dis."},{"issue":"2","key":"10.1016\/j.bcp.2019.04.009_b0330","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1093\/rheumatology\/37.2.189","article-title":"An initially double-blind controlled 96 week trial of depot methylprednisolone against oral prednisolone in the treatment of polymyalgia rheumatica","volume":"37","author":"Dasgupta","year":"1998","journal-title":"Br. J. Rheumatol."},{"issue":"10","key":"10.1016\/j.bcp.2019.04.009_b0335","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1136\/annrheumdis-2015-207492","article-title":"2015 Recommendations for the management of polymyalgia rheumatica: a European League Against Rheumatism\/American College of Rheumatology collaborative initiative","volume":"74","author":"Dejaco","year":"2015","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.bcp.2019.04.009_b0340","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/120638","article-title":"Leflunomide as a corticosteroid-sparing agent in giant cell arteritis and polymyalgia rheumatica: a case series","volume":"2013","author":"Diamantopoulos","year":"2013","journal-title":"Biomed. Res. Int."},{"issue":"5","key":"10.1016\/j.bcp.2019.04.009_b0345","doi-asserted-by":"crossref","first-page":"R176","DOI":"10.1186\/ar3140","article-title":"Effect of etanercept in polymyalgia rheumatica: a randomized controlled trial","volume":"12","author":"Kreiner","year":"2010","journal-title":"Arthritis Res. Ther."},{"issue":"9","key":"10.1016\/j.bcp.2019.04.009_b0350","doi-asserted-by":"crossref","first-page":"631","DOI":"10.7326\/0003-4819-146-9-200705010-00005","article-title":"Infliximab plus prednisone or placebo plus prednisone for the initial treatment of polymyalgia rheumatica: a randomized trial","volume":"146","author":"Salvarani","year":"2007","journal-title":"Ann. Intern. Med."},{"issue":"12","key":"10.1016\/j.bcp.2019.04.009_b0355","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1136\/annrheumdis-2013-203586","article-title":"Adalimumab for steroid sparing in patients with giant-cell arteritis: results of a multicentre randomised controlled trial","volume":"73","author":"Seror","year":"2014","journal-title":"Ann. Rheum. Dis."},{"issue":"5","key":"10.1016\/j.bcp.2019.04.009_b0360","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1136\/ard.2007.082115","article-title":"A double-blind placebo controlled trial of etanercept in patients with giant cell arteritis and corticosteroid side effects","volume":"67","author":"Martinez-Taboada","year":"2008","journal-title":"Ann. Rheum. Dis."},{"issue":"1","key":"10.1016\/j.bcp.2019.04.009_b0365","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1002\/art.20928","article-title":"Stable incidence of primary systemic vasculitides over five years: results from the German vasculitis register","volume":"53","author":"Reinhold-Keller","year":"2005","journal-title":"Arthrit. Rheum."},{"issue":"9","key":"10.1016\/j.bcp.2019.04.009_b0370","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1136\/annrheumdis-2016-209133","article-title":"EULAR\/ERA-EDTA recommendations for the management of ANCA-associated vasculitis","volume":"75","author":"Yates","year":"2016","journal-title":"Ann. Rheum. Dis."},{"issue":"1","key":"10.1016\/j.bcp.2019.04.009_b0375","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2017-000449","article-title":"Validation of the EULAR\/ERA-EDTA recommendations for the management of ANCA-associated vasculitis by disease content experts","volume":"3","author":"Yates","year":"2017","journal-title":"RMD Open"},{"issue":"10","key":"10.1016\/j.bcp.2019.04.009_b0380","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1093\/ndt\/16.10.2018","article-title":"Euvas. The value of pulse cyclophosphamide in ANCA-associated vasculitis: meta-analysis and critical review","volume":"16","author":"de Groot","year":"2001","journal-title":"Nephrol. Dial Transplant."},{"issue":"6","key":"10.1016\/j.bcp.2019.04.009_b0385","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1136\/annrheumdis-2011-200477","article-title":"Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up","volume":"71","author":"Harper","year":"2012","journal-title":"Ann. Rheum. Dis."},{"issue":"10","key":"10.1016\/j.bcp.2019.04.009_b0390","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1136\/ard.2003.019125","article-title":"Urinary bladder cancer in Wegener's granulomatosis: risks and relation to cyclophosphamide","volume":"63","author":"Knight","year":"2004","journal-title":"Ann. Rheum. Dis."},{"issue":"5","key":"10.1016\/j.bcp.2019.04.009_b0395","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1002\/1529-0131(200005)43:5<1021::AID-ANR10>3.0.CO;2-J","article-title":"An interdisciplinary approach to the care of patients with Wegener's granulomatosis: long-term outcome in 155 patients","volume":"43","author":"Reinhold-Keller","year":"2000","journal-title":"Arthrit. Rheum."},{"issue":"4","key":"10.1016\/j.bcp.2019.04.009_b0400","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.berh.2007.01.004","article-title":"Outpatient assessment of systemic vasculitis","volume":"21","author":"Nataraja","year":"2007","journal-title":"Best Pract. Res. Clin. Rheumatol."},{"issue":"10","key":"10.1016\/j.bcp.2019.04.009_b0405","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1093\/rheumatology\/kem146a","article-title":"BSR and BHPR guidelines for the management of adults with ANCA associated vasculitis","volume":"46","author":"Lapraik","year":"2007","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"10.1016\/j.bcp.2019.04.009_b0410","first-page":"228","article-title":"Systemic vasculitis treatment and monitoring update, 2008","volume":"66","author":"Yazici","year":"2008","journal-title":"Bull. NYU Hosp. Jt. Dis."},{"issue":"4","key":"10.1016\/j.bcp.2019.04.009_b0415","doi-asserted-by":"crossref","first-page":"685","DOI":"10.3109\/14397595.2013.874734","article-title":"Successful treatment of eosinophilic granulomatosis with polyangiitis (EGPA; formerly Churg-Strauss syndrome) with rituximab in a case refractory to glucocorticoids, cyclophosphamide, and IVIG","volume":"24","author":"Umezawa","year":"2014","journal-title":"Mod. Rheumatol."},{"issue":"6","key":"10.1016\/j.bcp.2019.04.009_b0420","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1016\/j.jaip.2017.07.027","article-title":"Rituximab as induction therapy in Eosinophilic Granulomatosis with polyangiitis refractory to conventional immunosuppressive treatment: a 36-month follow-up analysis","volume":"5","author":"Thiel","year":"2017","journal-title":"J. Aller. Clin. Immunol. Pract."},{"issue":"20","key":"10.1016\/j.bcp.2019.04.009_b0425","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1056\/NEJMoa1702079","article-title":"Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis","volume":"376","author":"Wechsler","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcp.2019.04.009_b0430","article-title":"Evaluation of clinical benefit from treatment with mepolizumab for eosinophilic granulomatosis with polyangiitis","author":"Steinfeld","year":"2018","journal-title":"J. Aller. Clin. Immunol."},{"key":"10.1016\/j.bcp.2019.04.009_b0435","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.2147\/TCRM.S159949","article-title":"Mepolizumab as the first targeted treatment for eosinophilic granulomatosis with polyangiitis: a review of current evidence and potential place in therapy","volume":"14","author":"Faverio","year":"2018","journal-title":"Ther. Clin. Risk Manag."},{"issue":"8","key":"10.1016\/j.bcp.2019.04.009_b0440","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1002\/1529-0131(200008)43:8<1841::AID-ANR21>3.0.CO;2-Q","article-title":"Cost-effectiveness of prophylaxis against Pneumocystis carinii pneumonia in patients with Wegner's granulomatosis undergoing immunosuppressive therapy","volume":"43","author":"Chung","year":"2000","journal-title":"Arthritis Rheum."},{"issue":"3","key":"10.1016\/j.bcp.2019.04.009_b0445","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1097\/BOR.0b013e3280d6471a","article-title":"Glucocorticoids: action and new therapeutic insights in rheumatoid arthritis","volume":"19","author":"Kirwan","year":"2007","journal-title":"Curr. Opin. Rheumatol."},{"issue":"1","key":"10.1016\/j.bcp.2019.04.009_b0450","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s00281-015-0550-0","article-title":"Lupus erythematosus revisited","volume":"38","author":"Kuhn","year":"2016","journal-title":"Semin. Immunopathol."},{"key":"10.1016\/j.bcp.2019.04.009_b0455","doi-asserted-by":"crossref","first-page":"16039","DOI":"10.1038\/nrdp.2016.39","article-title":"Systemic lupus erythematosus","volume":"2","author":"Kaul","year":"2016","journal-title":"Nat. Rev. Dis. Prim."},{"issue":"6","key":"10.1016\/j.bcp.2019.04.009_b0460","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.autrev.2004.04.002","article-title":"Surviving the butterfly and the wolf: mortality trends in systemic lupus erythematosus","volume":"3","author":"Borchers","year":"2004","journal-title":"Autoimmun. Rev."},{"issue":"2","key":"10.1016\/j.bcp.2019.04.009_b0465","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1136\/ard.2007.070367","article-title":"EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing committee for international clinical studies including therapeutics","volume":"67","author":"Bertsias","year":"2008","journal-title":"Ann. Rheum. Dis."},{"issue":"1","key":"10.1016\/j.bcp.2019.04.009_b0470","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s41584-018-0133-2","article-title":"New therapeutic strategies in systemic lupus erythematosus management","volume":"15","author":"Gatto","year":"2019","journal-title":"Nat. Rev. Rheumatol."},{"issue":"1","key":"10.1016\/j.bcp.2019.04.009_b0475","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/rheumatology\/kex286","article-title":"The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults","volume":"57","author":"Gordon","year":"2018","journal-title":"Rheumatol. (Oxford)"},{"issue":"1","key":"10.1016\/j.bcp.2019.04.009_b0480","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1093\/rheumatology\/kex291","article-title":"The British society for rheumatology guideline for the management of systemic lupus erythematosus in adults: executive summary","volume":"57","author":"Gordon","year":"2018","journal-title":"Rheumatology (Oxford)"},{"issue":"8","key":"10.1016\/j.bcp.2019.04.009_b0485","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1093\/rheumatology\/key170","article-title":"Comment on: The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults: reply","volume":"57","author":"Gordon","year":"2018","journal-title":"Rheumatology (Oxford)."},{"issue":"5","key":"10.1016\/j.bcp.2019.04.009_b0490","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1097\/BOR.0000000000000527","article-title":"Glucocorticoids and antimalarials in systemic lupus erythematosus: an update and future directions","volume":"30","author":"Ugarte","year":"2018","journal-title":"Curr. Opin. Rheumatol."},{"issue":"11","key":"10.1016\/j.bcp.2019.04.009_b0495","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1136\/annrheumdis-2012-201940","article-title":"Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR\/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis","volume":"71","author":"Bertsias","year":"2012","journal-title":"Ann. Rheum. Dis."},{"issue":"2","key":"10.1016\/j.bcp.2019.04.009_b0500","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1097\/01.ASN.0000108969.21691.5D","article-title":"The classification of glomerulonephritis in systemic lupus erythematosus revisited","volume":"15","author":"Weening","year":"2004","journal-title":"J. Am. Soc. Nephrol."},{"issue":"8822","key":"10.1016\/j.bcp.2019.04.009_b0505","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/0140-6736(92)92292-N","article-title":"Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis","volume":"340","author":"Boumpas","year":"1992","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.bcp.2019.04.009_b0510","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1002\/art.10461","article-title":"Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide","volume":"46","author":"Houssiau","year":"2002","journal-title":"Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.bcp.2019.04.009_b0515","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.steroids.2007.10.001","article-title":"Glucocorticoid receptor binding: a biphasic dependence on molecular size as revealed by the bilinear LinBiExp model","volume":"73","author":"Buchwald","year":"2008","journal-title":"Steroids"},{"issue":"5 Suppl 35","key":"10.1016\/j.bcp.2019.04.009_b0520","first-page":"S77","article-title":"Glucocorticoid use in rheumatoid arthritis: benefits, mechanisms, and risks","volume":"22","author":"Townsend","year":"2004","journal-title":"Clin. Exp. Rheumatol."},{"issue":"1","key":"10.1016\/j.bcp.2019.04.009_b0525","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1385\/JCD:1:1:65","article-title":"Glucocorticoid-induced osteoporosis: assessment and treatment","volume":"1","author":"Reid","year":"1998","journal-title":"J. Clin. Densitom."},{"issue":"9161","key":"10.1016\/j.bcp.2019.04.009_b0530","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/S0140-6736(98)04835-1","article-title":"Hip fractures attributable to corticosteroid use. Study of Osteoporotic Fractures Group","volume":"353","author":"Baltzan","year":"1999","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.bcp.2019.04.009_b0535","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1136\/ard.54.1.49","article-title":"Rheumatoid arthritis, corticosteroid therapy and hip fracture","volume":"54","author":"Cooper","year":"1995","journal-title":"Ann. Rheum. Dis."},{"issue":"8","key":"10.1016\/j.bcp.2019.04.009_b0540","first-page":"1495","article-title":"Limited bone loss due to corticosteroids; a systematic review of prospective studies in rheumatoid arthritis and other diseases","volume":"24","author":"Verhoeven","year":"1997","journal-title":"J. Rheumatol."},{"issue":"6","key":"10.1016\/j.bcp.2019.04.009_b0545","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1359\/jbmr.2000.15.6.993","article-title":"Use of oral corticosteroids and risk of fractures","volume":"15","author":"Van Staa","year":"2000","journal-title":"J. Bone Miner. Res."},{"issue":"2","key":"10.1016\/j.bcp.2019.04.009_b0550","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/nm.3074","article-title":"WNT signaling in bone homeostasis and disease: from human mutations to treatments","volume":"19","author":"Baron","year":"2013","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.bcp.2019.04.009_b0555","doi-asserted-by":"crossref","first-page":"8711","DOI":"10.1038\/s41598-018-26300-z","article-title":"Glucocorticoids suppress Wnt16 expression in osteoblasts in vitro and in vivo","volume":"8","author":"Hildebrandt","year":"2018","journal-title":"Sci. Rep."},{"issue":"6","key":"10.1016\/j.bcp.2019.04.009_b0560","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.cmet.2010.05.005","article-title":"Glucocorticoids suppress bone formation by attenuating osteoblast differentiation via the monomeric glucocorticoid receptor","volume":"11","author":"Rauch","year":"2010","journal-title":"Cell. Metab."},{"issue":"1","key":"10.1016\/j.bcp.2019.04.009_b0565","first-page":"158","article-title":"Effect of betaecdysterone on glucocorticoidinduced apoptosis and autophagy in osteoblasts","volume":"17","author":"Tang","year":"2018","journal-title":"Mol. Med. Rep."},{"issue":"4","key":"10.1016\/j.bcp.2019.04.009_b0570","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1159\/000180820","article-title":"Evidence for decreased tubular reabsorption of calcium in glucocorticoid-treated asthmatics","volume":"27","author":"Reid","year":"1987","journal-title":"Horm. Res."},{"issue":"9","key":"10.1016\/j.bcp.2019.04.009_b0575","doi-asserted-by":"crossref","first-page":"4033","DOI":"10.1210\/jc.2002-012101","article-title":"Clinical review 151: the role of parathyroid hormone in the pathogenesis of glucocorticoid-induced osteoporosis: a re-examination of the evidence","volume":"87","author":"Rubin","year":"2002","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"6","key":"10.1016\/j.bcp.2019.04.009_b0580","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/S8756-3282(01)00610-X","article-title":"Molecular mechanisms of glucocorticoid-induced osteoporosis","volume":"29","author":"Patschan","year":"2001","journal-title":"Bone"},{"issue":"5","key":"10.1016\/j.bcp.2019.04.009_b0585","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/0002-9343(85)90057-9","article-title":"Corticosteroid therapy associated with ischemic necrosis of bone in systemic lupus erythematosus","volume":"79","author":"Zizic","year":"1985","journal-title":"Am. J. Med."},{"issue":"3\u20134","key":"10.1016\/j.bcp.2019.04.009_b0590","first-page":"153","article-title":"Aseptic bone necrosis in patients on glucocorticoid replacement therapy","volume":"39","author":"Vreden","year":"1991","journal-title":"Neth. J. Med."},{"issue":"2","key":"10.1016\/j.bcp.2019.04.009_b0595","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/0002-9343(94)90131-7","article-title":"Low dose long-term corticosteroid therapy in rheumatoid arthritis: an analysis of serious adverse events","volume":"96","author":"Saag","year":"1994","journal-title":"Am. J. Med."},{"issue":"8","key":"10.1016\/j.bcp.2019.04.009_b0600","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1002\/art.40137","article-title":"2017 American College of rheumatology guideline for the prevention and treatment of glucocorticoid-induced osteoporosis","volume":"69","author":"Buckley","year":"2017","journal-title":"Arthr. Rheumatol."},{"issue":"5","key":"10.1016\/j.bcp.2019.04.009_b0605","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/0002-9343(92)90578-Y","article-title":"Risk factors for coronary artery disease in patients with systemic lupus erythematosus","volume":"93","author":"Petri","year":"1992","journal-title":"Am. J. Med."},{"issue":"3","key":"10.1016\/j.bcp.2019.04.009_b0610","first-page":"445","article-title":"Cardiovascular morbidity and mortality in patients with seropositive rheumatoid arthritis in Northern Sweden","volume":"24","author":"Wallberg-Jonsson","year":"1997","journal-title":"J. Rheumatol."},{"issue":"Suppl 7","key":"10.1016\/j.bcp.2019.04.009_b0615","doi-asserted-by":"crossref","first-page":"381s","DOI":"10.1042\/cs061381s","article-title":"Does long-term low-dose corticosteroid therapy cause hypertension?","volume":"61","author":"Jackson","year":"1981","journal-title":"Clin. Sci. (Lond)."},{"issue":"3","key":"10.1016\/j.bcp.2019.04.009_b0620","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1002\/j.2040-4603.2014.tb00569.x","article-title":"The multifaceted mineralocorticoid receptor","volume":"4","author":"Gomez-Sanchez","year":"2014","journal-title":"Compr. Physiol."},{"issue":"10","key":"10.1016\/j.bcp.2019.04.009_b0625","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"N. Engl. J. Med."},{"issue":"14","key":"10.1016\/j.bcp.2019.04.009_b0630","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"N. Engl. J. Med."},{"issue":"23","key":"10.1016\/j.bcp.2019.04.009_b0635","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1056\/NEJMra000050","article-title":"Aldosterone in congestive heart failure","volume":"345","author":"Weber","year":"2001","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.bcp.2019.04.009_b0640","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1136\/hrt.2003.031492","article-title":"Glucocorticoid treatment and cardiovascular disease","volume":"90","author":"Ng","year":"2004","journal-title":"Heart"},{"issue":"8","key":"10.1016\/j.bcp.2019.04.009_b0645","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1176\/ajp.146.8.1076","article-title":"Mania triggered by a steroid nasal spray in a patient with stable bipolar disorder","volume":"146","author":"Goldstein","year":"1989","journal-title":"Am. J. Psychiat."},{"issue":"10","key":"10.1016\/j.bcp.2019.04.009_b0650","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1001\/archpsyc.1990.01810220079010","article-title":"Prednisone effects on neurochemistry and behavior. Preliminary findings","volume":"47","author":"Wolkowitz","year":"1990","journal-title":"Arch. Gen. Psychiat."},{"issue":"Suppl 1","key":"10.1016\/j.bcp.2019.04.009_b0655","doi-asserted-by":"crossref","first-page":"S94","DOI":"10.4103\/0976-500X.120975","article-title":"Corticosteroid-related central nervous system side effects","volume":"4","author":"Ciriaco","year":"2013","journal-title":"J. Pharmacol. Pharmacother."},{"issue":"6","key":"10.1016\/j.bcp.2019.04.009_b0660","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1023\/A:1023271325728","article-title":"Effects of dexamethasone on K(+)-evoked glutamate release from rat hippocampal slices","volume":"28","author":"Ioannou","year":"2003","journal-title":"Neurochem. Res."},{"issue":"3","key":"10.1016\/j.bcp.2019.04.009_b0665","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1002\/art.21984","article-title":"Population-based assessment of adverse events associated with long-term glucocorticoid use","volume":"55","author":"Curtis","year":"2006","journal-title":"Arthrit. Rheum."},{"issue":"4","key":"10.1016\/j.bcp.2019.04.009_b0670","doi-asserted-by":"crossref","first-page":"383","DOI":"10.31887\/DCNS.2006.8.4\/ssmith","article-title":"The role of the hypothalamic-pituitary-adrenal axis in neuroendocrine responses to stress","volume":"8","author":"Smith","year":"2006","journal-title":"Dialog. Clin Neurosci."},{"issue":"10","key":"10.1016\/j.bcp.2019.04.009_b0675","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18102201","article-title":"Treatment with synthetic glucocorticoids and the hypothalamus-pituitary-adrenal axis","volume":"18","author":"Paragliola","year":"2017","journal-title":"Int. J. Mol. Sci."},{"issue":"Suppl 2","key":"10.1016\/j.bcp.2019.04.009_b0680","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1186\/ar4687","article-title":"Circadian rhythms in rheumatology\u2013a glucocorticoid perspective","volume":"16","author":"Spies","year":"2014","journal-title":"Arthrit. Res. Ther."},{"issue":"Suppl 1","key":"10.1016\/j.bcp.2019.04.009_b0685","first-page":"3","article-title":"Rheumatoid arthritis: circadian rhythms in disease activity, signs and symptoms, and rationale for chronotherapy with corticosteroids and other medications","volume":"70","author":"Haus","year":"2012","journal-title":"Bull. NYU Hosp. Jt. Dis."},{"issue":"6","key":"10.1016\/j.bcp.2019.04.009_b0690","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1176\/appi.psy.42.6.461","article-title":"Corticosteroid-induced psychotic and mood disorders: diagnosis defined by DSM-IV and clinical pictures","volume":"42","author":"Wada","year":"2001","journal-title":"Psychosomatics"},{"issue":"2","key":"10.1016\/j.bcp.2019.04.009_b0695","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S0033-3182(93)71910-6","article-title":"Treatment of depression with fluoxetine in corticosteroid-dependent central nervous system Sjogren's syndrome","volume":"34","author":"Wyszynski","year":"1993","journal-title":"Psychosomatics"},{"issue":"3","key":"10.1016\/j.bcp.2019.04.009_b0700","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/j.1365-4632.2009.04322.x","article-title":"Prevention and treatment of systemic glucocorticoid side effects","volume":"49","author":"Moghadam-Kia","year":"2010","journal-title":"Int. J. Dermatol."},{"issue":"1","key":"10.1016\/j.bcp.2019.04.009_b0705","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/0003-4819-136-1-200201010-00006","article-title":"Siewertsz Van Reesema DR, Bijlsma JW. Low-dose prednisone therapy for patients with early active rheumatoid arthritis: clinical efficacy, disease-modifying properties, and side effects: a randomized, double-blind, placebo-controlled clinical trial","volume":"136","author":"van Everdingen","year":"2002","journal-title":"Ann. Intern. Med."},{"issue":"1\u20132","key":"10.1016\/j.bcp.2019.04.009_b0710","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.mce.2007.05.015","article-title":"Glucocorticoids, metabolism and metabolic diseases","volume":"275","author":"Vegiopoulos","year":"2007","journal-title":"Mol. Cell. Endocrinol."},{"issue":"3","key":"10.1016\/j.bcp.2019.04.009_b0715","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1530\/EJE-16-0653","article-title":"Metformin prevents metabolic side effects during systemic glucocorticoid treatment","volume":"176","author":"Seelig","year":"2017","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.bcp.2019.04.009_b0720","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1136\/pgmj.40.469.660","article-title":"Clinical features of the diabetic syndrome appearing after steroid therapy","volume":"40","author":"Miller","year":"1964","journal-title":"Postgrad. Med. J."},{"issue":"9398","key":"10.1016\/j.bcp.2019.04.009_b0725","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1016\/S0140-6736(03)14904-5","article-title":"Glucocorticoids and invasive fungal infections","volume":"362","author":"Lionakis","year":"2003","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.bcp.2019.04.009_b0730","doi-asserted-by":"crossref","first-page":"5","DOI":"10.4065\/71.1.5","article-title":"Pneumocystis carinii pneumonia in patients without acquired immunodeficiency syndrome: associated illness and prior corticosteroid therapy","volume":"71","author":"Yale","year":"1996","journal-title":"Mayo Clin. Proc."},{"issue":"4","key":"10.1016\/j.bcp.2019.04.009_b0735","doi-asserted-by":"crossref","first-page":"509","DOI":"10.3109\/s10165-011-0523-7","article-title":"Prognosis of pneumocystis pneumonia complicated in patients with rheumatoid arthritis (RA) and non-RA rheumatic diseases","volume":"22","author":"Yoshida","year":"2012","journal-title":"Mod. Rheumatol."},{"issue":"Suppl 1","key":"10.1016\/j.bcp.2019.04.009_b0740","first-page":"29","article-title":"Pneumocystis jirovecii pneumonia in rheumatoid arthritis patients: risks and prophylaxis recommendations","volume":"9","author":"Mori","year":"2015","journal-title":"Clin. Med. Insights Circ. Respir. Pulm. Med."},{"issue":"2","key":"10.1016\/j.bcp.2019.04.009_b0745","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1136\/ard.2007.072967","article-title":"Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis","volume":"67","author":"Takeuchi","year":"2008","journal-title":"Ann. Rheum. Dis."},{"issue":"5","key":"10.1016\/j.bcp.2019.04.009_b0750","doi-asserted-by":"crossref","first-page":"898","DOI":"10.3899\/jrheum.080791","article-title":"Postmarketing surveillance of the safety and effectiveness of etanercept in Japan","volume":"36","author":"Koike","year":"2009","journal-title":"J. Rheumatol."},{"issue":"6","key":"10.1016\/j.bcp.2019.04.009_b0755","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1007\/s10620-006-9250-x","article-title":"Pneumocystis jiroveci (carinii) pneumonia after infliximab therapy: a review of 84 cases","volume":"52","author":"Kaur","year":"2007","journal-title":"Dig. Dis. Sci."},{"issue":"12","key":"10.1016\/j.bcp.2019.04.009_b0760","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1093\/cid\/ciu185","article-title":"Biologic therapies in rheumatoid arthritis and the risk of opportunistic infections: a meta-analysis","volume":"58","author":"Kourbeti","year":"2014","journal-title":"Clin. Infect. Dis."},{"issue":"5","key":"10.1016\/j.bcp.2019.04.009_b0765","doi-asserted-by":"crossref","first-page":"2502","DOI":"10.4049\/jimmunol.133.5.2502","article-title":"Lymphocyte changes during chronic administration of and withdrawal from corticosteroids: relation to Pneumocystis carinii pneumonia","volume":"133","author":"Walzer","year":"1984","journal-title":"J. Immunol."},{"issue":"6","key":"10.1016\/j.bcp.2019.04.009_b0770","doi-asserted-by":"crossref","first-page":"849","DOI":"10.3109\/s10165-012-0615-z","article-title":"Pneumocystis jirovecii pneumonia associated with etanercept treatment in patients with rheumatoid arthritis: a retrospective review of 15 cases and analysis of risk factors","volume":"22","author":"Tanaka","year":"2012","journal-title":"Mod. Rheumatol."},{"issue":"3","key":"10.1016\/j.bcp.2019.04.009_b0775","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1002\/art.24283","article-title":"Pneumocystis jiroveci pneumonia in patients with rheumatoid arthritis treated with infliximab: a retrospective review and case-control study of 21 patients","volume":"61","author":"Komano","year":"2009","journal-title":"Arthritis Rheum."},{"issue":"7","key":"10.1016\/j.bcp.2019.04.009_b0780","first-page":"1186","article-title":"Risk factors for Pneumocystis carinii pneumonia in patients with polymyositis\/dermatomyositis or systemic lupus erythematosus","volume":"23","author":"Kadoya","year":"1996","journal-title":"J. Rheumatol."},{"issue":"1","key":"10.1016\/j.bcp.2019.04.009_b0785","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.semarthrit.2015.01.007","article-title":"Pneumocystis jirovecci pneumonia in connective tissue diseases: Comparison with other immunocompromised patients","volume":"45","author":"Teichtahl","year":"2015","journal-title":"Sem. Arthrit. Rheum."},{"issue":"3","key":"10.1016\/j.bcp.2019.04.009_b0790","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/eci.12410","article-title":"Frequency, risk factors and prophylaxis of infection in ANCA-associated vasculitis","volume":"45","author":"Kronbichler","year":"2015","journal-title":"Eur. J. Clin. Invest."},{"issue":"5","key":"10.1016\/j.bcp.2019.04.009_b0795","first-page":"292","article-title":"Prescriptions for a toxic combination: use of methotrexate plus trimethoprim-sulfamethoxazole in the United States","volume":"107","author":"Davis","year":"2014","journal-title":"South Med J."},{"issue":"1","key":"10.1016\/j.bcp.2019.04.009_b0800","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1093\/rheumatology\/kei193","article-title":"Influence of methotrexate, TNF blockers and prednisolone on antibody responses to pneumococcal polysaccharide vaccine in patients with rheumatoid arthritis","volume":"45","author":"Kapetanovic","year":"2006","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"10.1016\/j.bcp.2019.04.009_b0805","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1056\/NEJM198307073090105","article-title":"Association of adrenocorticosteroid therapy and peptic-ulcer disease","volume":"309","author":"Messer","year":"1983","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.bcp.2019.04.009_b0810","doi-asserted-by":"crossref","first-page":"735","DOI":"10.7326\/0003-4819-114-9-735","article-title":"Corticosteroid use and peptic ulcer disease: role of nonsteroidal anti-inflammatory drugs","volume":"114","author":"Piper","year":"1991","journal-title":"Ann. Intern. Med."},{"issue":"13","key":"10.1016\/j.bcp.2019.04.009_b0815","doi-asserted-by":"crossref","first-page":"7563","DOI":"10.1073\/pnas.96.13.7563","article-title":"Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis","volume":"96","author":"Warner","year":"1999","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"4","key":"10.1016\/j.bcp.2019.04.009_b0820","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1152\/physrev.00004.2008","article-title":"Prostaglandins, NSAIDs, and gastric mucosal protection: why doesn't the stomach digest itself?","volume":"88","author":"Wallace","year":"2008","journal-title":"Physiol. Rev."},{"issue":"Suppl 1","key":"10.1016\/j.bcp.2019.04.009_b0825","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1159\/000089789","article-title":"Microbial flora in NSAID-induced intestinal damage: a role for antibiotics?","volume":"73","author":"Lanas","year":"2006","journal-title":"Digestion"},{"issue":"1","key":"10.1016\/j.bcp.2019.04.009_b0830","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1056\/NEJM199707033370102","article-title":"Use of inhaled corticosteroids and the risk of cataracts","volume":"337","author":"Cumming","year":"1997","journal-title":"N. Engl. J. Med."},{"issue":"9083","key":"10.1016\/j.bcp.2019.04.009_b0835","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/S0140-6736(97)03392-8","article-title":"Risk of ocular hypertension or open-angle glaucoma in elderly patients on oral glucocorticoids","volume":"350","author":"Garbe","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.bcp.2019.04.009_b0840","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ejphar.2016.06.018","article-title":"Glucocorticoid therapy and ocular hypertension","volume":"787","author":"Dibas","year":"2016","journal-title":"Eur. J. Pharmacol."},{"issue":"2","key":"10.1016\/j.bcp.2019.04.009_b0845","first-page":"163","article-title":"Corticosteroid-induced ocular hypertension and glaucoma: a brief review and update of the literature","volume":"17","author":"Jones","year":"2006","journal-title":"Curr. Opin. Ophthalmol."},{"issue":"2","key":"10.1016\/j.bcp.2019.04.009_b0850","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.exer.2006.09.022","article-title":"Dexamethasone inhibition of trabecular meshwork cell phagocytosis and its modulation by glucocorticoid receptor beta","volume":"84","author":"Zhang","year":"2007","journal-title":"Exp. Eye Res."},{"issue":"1","key":"10.1016\/j.bcp.2019.04.009_b0855","first-page":"281","article-title":"Glucocorticoid-induced formation of cross-linked actin networks in cultured human trabecular meshwork cells","volume":"35","author":"Clark","year":"1994","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"issue":"10","key":"10.1016\/j.bcp.2019.04.009_b0860","doi-asserted-by":"crossref","first-page":"6502","DOI":"10.1167\/iovs.13-12447","article-title":"Dexamethasone induces cross-linked actin networks in trabecular meshwork cells through noncanonical wnt signaling","volume":"54","author":"Yuan","year":"2013","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"issue":"7","key":"10.1016\/j.bcp.2019.04.009_b0865","doi-asserted-by":"crossref","first-page":"3184","DOI":"10.1167\/iovs.06-1403","article-title":"Presence of an established calcification marker in trabecular meshwork tissue of glaucoma donors","volume":"48","author":"Xue","year":"2007","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"issue":"3","key":"10.1016\/j.bcp.2019.04.009_b0870","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1080\/03009740601154111","article-title":"The effect of methylprednisolone on proliferation of PBMCs obtained from steroid-sensitive and steroid-resistant rheumatoid arthritis patients","volume":"36","author":"Sliwinska-Stanczyk","year":"2007","journal-title":"Scand. J. Rheumatol."},{"issue":"6","key":"10.1016\/j.bcp.2019.04.009_b0875","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.tcb.2006.04.005","article-title":"Glucocorticoid receptor isoforms generate transcription specificity","volume":"16","author":"Lu","year":"2006","journal-title":"Trends Cell Biol."},{"key":"10.1016\/j.bcp.2019.04.009_b0880","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1196\/annals.1351.001","article-title":"The physiology of human glucocorticoid receptor beta (hGRbeta) and glucocorticoid resistance","volume":"1069","author":"Lewis-Tuffin","year":"2006","journal-title":"Ann. N.Y. Acad. Sci."},{"issue":"12","key":"10.1016\/j.bcp.2019.04.009_b0885","doi-asserted-by":"crossref","first-page":"5695","DOI":"10.1210\/jc.2002-020970","article-title":"11beta-hydroxysteroid dehydrogenase types 1 and 2: an important pharmacokinetic determinant for the activity of synthetic mineralo- and glucocorticoids","volume":"87","author":"Diederich","year":"2002","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"7","key":"10.1016\/j.bcp.2019.04.009_b0890","doi-asserted-by":"crossref","first-page":"E747","DOI":"10.1152\/ajpendo.00639.2012","article-title":"Effects of 11beta-hydroxysteroid dehydrogenase-1 inhibition on hepatic glycogenolysis and gluconeogenesis","volume":"304","author":"Winnick","year":"2013","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"issue":"1","key":"10.1016\/j.bcp.2019.04.009_b0895","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1053\/beem.2000.0119","article-title":"Cortisol metabolism and the role of 11beta-hydroxysteroid dehydrogenase","volume":"15","author":"Tomlinson","year":"2001","journal-title":"Best. Pract. Res. Clin. Endocrinol. Metab."},{"issue":"4","key":"10.1016\/j.bcp.2019.04.009_b0900","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.cytogfr.2010.04.003","article-title":"Crosstalk between TNF and glucocorticoid receptor signaling pathways","volume":"21","author":"Van Bogaert","year":"2010","journal-title":"Cytokine Growth Factor Rev."},{"issue":"8","key":"10.1016\/j.bcp.2019.04.009_b0905","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.15252\/emmm.201405010","article-title":"Glucocorticoid-induced microRNA-511 protects against TNF by down-regulating TNFR1","volume":"7","author":"Puimege","year":"2015","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.bcp.2019.04.009_b0910","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.pharmthera.2015.05.001","article-title":"Selective glucocorticoid receptor modulation: New directions with non-steroidal scaffolds","volume":"152","author":"Sundahl","year":"2015","journal-title":"Pharmacol. Ther."},{"issue":"2\u20133","key":"10.1016\/j.bcp.2019.04.009_b0915","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.jsbmb.2010.02.027","article-title":"Selective Glucocorticoid Receptor modulators","volume":"120","author":"De Bosscher","year":"2010","journal-title":"J. Steroid Biochem. Mol. Biol."},{"issue":"12","key":"10.1016\/j.bcp.2019.04.009_b0920","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0188810","article-title":"Efficacy and safety of selective glucocorticoid receptor modulators in comparison to glucocorticoids in arthritis, a systematic review","volume":"12","author":"Safy","year":"2017","journal-title":"PLoS One"},{"issue":"8","key":"10.1016\/j.bcp.2019.04.009_b0925","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1111\/1756-185X.13053","article-title":"Improved disease activity with fosdagrocorat (PF-04171327), a partial agonist of the glucocorticoid receptor, in patients with rheumatoid arthritis: a Phase 2 randomized study","volume":"20","author":"Stock","year":"2017","journal-title":"Int. J. Rheum. Dis."},{"issue":"6","key":"10.1016\/j.bcp.2019.04.009_b0930","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S1094-5539(03)00105-6","article-title":"Soft steroids: a new approach to the treatment of inflammatory airways diseases","volume":"16","author":"Belvisi","year":"2003","journal-title":"Pulm. Pharmacol. Ther."},{"issue":"10","key":"10.1016\/j.bcp.2019.04.009_b0935","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1016\/j.rmed.2005.05.024","article-title":"Once-daily ciclesonide 80 or 320 microg for 12 weeks is safe and effective in patients with persistent asthma","volume":"99","author":"Langdon","year":"2005","journal-title":"Respir. Med."},{"issue":"2","key":"10.1016\/j.bcp.2019.04.009_b0940","first-page":"83","article-title":"Drug therapy in asthma bronchiale in the new millennium","volume":"57","author":"Szelenyi","year":"2002","journal-title":"Pharmazie"},{"issue":"12","key":"10.1016\/j.bcp.2019.04.009_b0945","doi-asserted-by":"crossref","first-page":"2910","DOI":"10.1007\/s11095-008-9683-3","article-title":"Synthesis and evaluation of a well-defined HPMA copolymer-dexamethasone conjugate for effective treatment of rheumatoid arthritis","volume":"25","author":"Liu","year":"2008","journal-title":"Pharm. Res."},{"issue":"1","key":"10.1016\/j.bcp.2019.04.009_b0950","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1007\/s11095-015-1776-1","article-title":"The evaluation of the therapeutic efficacy and side effects of a macromolecular dexamethasone prodrug in the collagen-induced arthritis mouse model","volume":"33","author":"Quan","year":"2016","journal-title":"Pharm. Res."},{"key":"10.1016\/j.bcp.2019.04.009_b0955","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.jconrel.2019.01.015","article-title":"Dexamethasone palmitate nanoparticles: an efficient treatment for rheumatoid arthritis","volume":"296","author":"Lorscheider","year":"2019","journal-title":"J. Control Release."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295219301443?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295219301443?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T13:07:56Z","timestamp":1757768876000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295219301443"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":191,"alternative-id":["S0006295219301443"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2019.04.009","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risks and benefits of corticosteroids in arthritic diseases in the clinic","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2019.04.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}